| 2021-12-16 |
复牌提示：
2021-12-15 19:50:04 停牌，复牌日期 2021-12-17
|
| 2021-10-14 |
股东大会：
将于2021-11-16召开股东大会
会议内容 ▼▲
- 1.To approve the acquisition of Itamar by ZOLL Medical Corporation (“Parent”), including the approval of: (i) the Agreement and Plan of Merger, dated September 13, 2021 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Parent, Zeus Merger Sub Ltd., an Israeli company and a wholly owned subsidiary of Parent (“Merger Sub”) and, solely for the limited purposes set forth therein, Asahi Kasei Corporation (“Guarantor”); (ii) the merger of Merger Sub with and into the Company in accordance with Sections 314-327 of the Israeli Companies Law, 5759-1999 (the “ICL”), following which Merger Sub will cease to exist as a separate legal entity and the Company will become a wholly owned subsidiary of Parent (the “Merger”); (iii) the consideration of $1.0333333 in cash, without interest and subject to applicable withholding taxes, to be received for each ordinary share, par value NIS 0.01 per share, of the Company (the “Ordinary Shares”), including with respect to the Ordinary Shares underlying the Company’s American Depositary Shares, each representing thirty (30) Ordinary Shares (“ADSs”), owned as of immediately prior to the effective time of the Merger; (iv) the cancellation of each outstanding option to purchase Ordinary Shares or ADSs (including those granted to the Company’s directors and officers) in exchange for the right to receive a cash payment, in accordance with the Merger Agreement; (v) the cancellation of each outstanding restricted share unit (including those granted to the Company’s directors and officers) in exchange for the right to receive a cash payment, in accordance with the Merger Agreement; and (vi) all other transactions and arrangements contemplated by the Merger Agreement (collectively, the “Merger Proposal”);
2.To approve the adjournment of the Meeting to a later date or dates, if necessary, to solicit additional proxies if there are insufficient votes to approve the Merger Proposal at the time of the Meeting (the “Adjournment Proposal”);
3.To elect Giora Yaron, Ilan Biran, Christopher M. Cleary, Scott P. Serota, Brad Fluegel and Marga Ortigas-Wedekind as directors of the Company (the “Director Proposal”);
4.To approve amendments to the Company’s compensation policy governing the compensation of the Company’s office holders (the “Compensation Policy Proposal”);
5.To approve a modification to the base compensation of the Company’s President and Chief Executive Officer (the “CEO Salary Proposal”);
6.To approve the reappointment of Somekh Chaikin, a member of KPMG International, as the Company’s independent auditor, and to authorize the Company’s Board of Directors to delegate to the Audit Committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services (the “Auditor Proposal”);
7.To review and discuss the Company’s consolidated financial statements for the year ended December 31, 2020.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-10 |
财报披露：
美东时间 2021-08-10 盘前发布财报
|
| 2021-03-29 |
详情>>
股本变动：
变动后总股本1638.71万股
|
| 2021-03-29 |
详情>>
业绩披露：
2020年年报每股收益-0.03美元,归母净利润-1093.9万美元,同比去年增长-107.65%
|
| 2020-07-15 |
股东大会：
将于2020-08-19召开股东大会
会议内容 ▼▲
- 1.To reelect Messrs. Giora Yaron, Ilan Biran, Jonathan Kolber, Sami Totah and Christopher M. Cleary as directors of the Company;
2.To approve a modification of the terms of compensation of our non-employee directors;
3.To approve a modification to the bonus plan of our President and Chief Executive Officer;
4.To approve the reappointment of Somekh Chaikin, a member of KPMG International, as our independent auditors, and to authorize our Board of Directors to delegate to the Audit Committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services;
5.To review and discuss our consolidated financial statements for the year ended December 31, 2019.
|
| 2020-04-03 |
详情>>
业绩披露：
2019年年报每股收益-0.02美元,归母净利润-526.8万美元,同比去年增长-204.68%
|
| 2020-02-11 |
股东大会：
将于2020-03-18召开股东大会
会议内容 ▼▲
- 1.To approve amendments to the Company’s Compensation Policy and to approve and ratify the purchase of directors’ and officers’ liability insurance policy;
2.To clarify the Company’s equity-based award policy for non-employee directors, including external directors;
3.To approve the grant to the Company’s President and Chief Executive Officer of (i) performance-based stock options and performance-based RSUs in exchange for a waiver of certain prior grants and (ii) service stock options;
4.To approve a special bonus to the Company’s President and Chief Executive Officer.
|
| 2019-04-23 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To reelect Messrs. Giora Yaron, Martin Gerstel, Ilan Biran, Jonathan Kolber, Sami Totah and Christopher M. Cleary as directors of the Company;
2.To reelect Ms. Yaffa Krindel Sieradzki and Ms. Zipora (Tzipi) Ozer-Armon as external directors of the Company;
3.To approve an amended Compensation Policy for Executive Officers and Directors;
4.To approve grants of stock options to our non-employee directors;
5.To approve a special bonus to Mr. Gilad Glick, our President and Chief Executive Officer;
6.To approve the reappointment of Somekh Chaikin, a member of KPMG International, as our independent auditors, and to authorize our Board of Directors to delegate to the audit committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services;
7.To review and discuss our consolidated financial statements for the year ended December 31, 2018.
|
| 2019-04-10 |
详情>>
业绩披露：
2018年年报每股收益-0.01美元,归母净利润-172.9万美元,同比去年增长67.38%
|
| 2019-02-13 |
详情>>
业绩披露：
2016年年报每股收益-0.05美元,归母净利润-1440.3万美元,同比去年增长-540.99%
|
| 2019-02-13 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-0.01美元,归母净利润-151.5万美元,同比去年增长50.88%
|
| 2019-02-13 |
详情>>
业绩披露：
2017年年报每股收益-0.02美元,归母净利润-530.1万美元,同比去年增长63.20%
|
| 2018-11-26 |
详情>>
业绩披露：
2018年中报每股收益0.00美元,归母净利润-31.2万美元,同比去年增长81.54%
|